Drugs / FTC/TDF FDC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02431247 Comparator | Jul 2015 → Mar 2017 | immunodeficiency disease | Janssen Sciences Ireland UC | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FTC/TDF FDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02431247 ↗ |
| Known as | TDF | “Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding...” NCT02431247 ↗ |
| Route | Oral | “A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.” NCT02431247 ↗ |